Search

Search Constraints

You searched for: Author/Creator Calvaruso, V.

Search Results

1. A multicentre prospective study response to treatment in genotype 3 and 1b infected patients with sickest liver cirrhosis: SVR 4 is not a reliable measure. (8th October 2016)

2. AA genotype of deSNP rs6726639 of MERTK gene is associated with development of Hepatocellular Carcinoma after eradication of Hepatitis C Virus infection. (February 2019)

3. AF.87 RESIST-HCV CRITERIA ARE ABLE TO RULE OUT ESOPHAGEAL VARICES PROGRESSION IN PATIENTS WITH HCV CIRRHOSIS TREATED BY DIRECT-ACTING ANTIVIRAL AGENTS(DAAS). (September 2021)

4. Changes in 13C-aminopyrine breath test predict liver-related events and death in patients with HCV-related previous decompensated child A5 or child A6 to B cirrhosis who achieve SVR after DAA therapy. (February 2019)

5. Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance. (February 2019)

6. Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy. Issue 1 (February 2018)

7. Current epidemiology of HCV in Sicily: the RESIST-HCV model. (October 2019)

8. Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. (February 2019)

9. Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort. Issue 1 (February 2018)

10. Early occurrence of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis treated with direct-acting antivirals (DAAs). Issue 1 (16th February 2017)